Exosome RNA Exosome RNA Research & Industry News
Delivering drugs to the back of the eye has always been a major challenge. The eye is protected by multiple biological barriers that prevent most treatments from reaching the retina, often requiring invasive injections. New research at Shenyang Pharmaceutical University explored a surprising solution using exosomes derived from semen.
Exosomes are tiny vesicles naturally released by cells that can carry proteins and other molecules. Because they are biologically compatible and small in size, they can move through tissues more easily than many synthetic drug carriers. The researchers discovered that semen-derived exosomes have a natural ability to cross eye barriers, partly due to proteins on their surface that temporarily loosen tight junctions between cells.
Using this property, the team developed a novel eye drop formulation. They modified the exosomes with folic acid to help target cancer cells and loaded them with a therapeutic system made of carbon-based nanoparticles, manganese dioxide, and an enzyme that produces reactive oxygen species. This combination was designed to selectively kill retinoblastoma cells, a type of eye cancer.
Schematic illustration of the therapeutic role of FA-SEVs@CMG in RB
SEVs could temporarily disrupt the tight junctions of the ocular barrier, facilitating the delivery of CMG to the RB tissue via both corneal and scleral pathways, thereby achieving an omnidirectional attack around RB. FA-SEVs@CMG generated substantial oxidative stress in response to the TME, which induced tumor cell death through a synergistic mechanism involving ferroptosis, apoptosis, and autophagy. Excessive oxidative stress induced autophagy, which activated the extrinsic apoptotic pathway (BID-Caspase-8), further promoting apoptosis and inducing the self-destruction of RB cells.
When applied as eye drops, these engineered exosomes were able to travel through both the cornea and conjunctiva to reach the back of the eye. Once inside tumor cells, the therapeutic cargo triggered high levels of oxidative stress, disrupting normal cellular processes and leading to cancer cell death.
Importantly, in animal models, this approach reduced tumor growth while preserving normal retinal function. This suggests that exosome-based eye drops could offer a noninvasive alternative to current treatments that rely on injections directly into the eye.
Overall, the work highlights how extracellular vesicles can be adapted for targeted drug delivery in challenging environments like the eye. It opens up new possibilities for treating retinal diseases and cancers with simple, noninvasive therapies.
